Clinical Outcomes of PRX S With Standardized Home Care in Mild-to-Moderate Facial Acne. (PRXS-SINGLE)
Changes in Inflammatory Lesion Count, Tolerability, and Clinical and Instrumental Skin Parameters Following Five PRX S Sessions Combined With Standardized Home Care in Adults With Mild-to-Moderate Facial Acne: A Prospective, Single-Arm, Open-Label Clinical Study.
This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.
The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.
The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.
Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.
All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.
The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.
The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.
Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.
All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Anna Deda, PhD
- Numero di telefono: +48 500 233 457
- Email: adeda@sum.edu.pl
Luoghi di studio
-
-
-
Mysłowice, Polonia, 41-400
- AJ Med
-
Contatto:
- Anna Deda
- Numero di telefono: +48 500 233 457
- Email: adeda@sum.edu.pl
-
Sosnowiec, Polonia, 41-208
- Department of Practical Cosmetology and Skin Diagnostics
-
Contatto:
- Anna Deda, PhD
- Numero di telefono: +48 500 233 457
- Email: adeda@sum.edu.pl
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 18-60 years.
- Mild-to-moderate facial acne vulgaris, defined as Investigator's Global Assessment (IGA) grade 2 or 3, confirmed by a dermatologist at baseline (T0).
- Presence of at least five inflammatory facial acne lesions (papules and/or pustules) at baseline.
- Provision of written informed consent to participate in the study and undergo study-related assessments and documentation.
- No contraindications to the study products and confirmation by a dermatologist that the treatment regimen is clinically appropriate.
- Ability and willingness to attend scheduled study visits and comply with the standardized home skin-care regimen.
- No urgent need for alternative acne treatment that is not provided within the study protocol.
Exclusion Criteria:
- Investigator's Global Assessment (IGA) grade 0, 1, or 4.
- Severe or nodulocystic acne, deep inflammatory lesions, or rapidly progressive acne scarring requiring alternative medical management.
- Pregnancy or breastfeeding.
- Known hypersensitivity to any component of the study products.
- Active herpes simplex infection, other skin infections, wounds, erosions, or burns in the treatment area.
- Active atopic dermatitis, seborrheic dermatitis, or other skin conditions that may interfere with study assessments.
- Skin malignancy or suspicious lesions in the treatment area.
- Medical conditions or concurrent therapies that may significantly increase treatment-related risks or interfere with the interpretation of study outcomes.
- Use of topical retinoids within 30 days before baseline (T0).
- Completion of anti-acne antibiotic therapy less than 3 months before baseline (T0).
- Completion of isotretinoin therapy less than 6 months before baseline (T0).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: PRX S Treatment Combined With Standardized Home Care
Participants will receive five professional PRX S facial treatments at approximately 14-day intervals (days 0, 14, 28, 42, and 56), combined with standardized home skin care consisting of WIQO Nourishing Cream for Normal and Combination Skin applied in the morning and WIQO Balancing Cream applied in the evening. Home care will continue throughout the study, including the follow-up period. Clinical and instrumental assessments will be performed at baseline (T0), after three completed treatments (T1), two weeks after the fifth treatment (T2), and two calendar months after T2 (T3). All participants will receive the same combined regimen, with no placebo or comparator group. |
PRX S is a two-phase topical preparation activated immediately before professional application according to the manufacturer's instructions for use. Participants will undergo five facial treatment sessions at approximately 14-day intervals (days 0, 14, 28, 42, and 56). The procedure will be performed using a standardized protocol appropriate for mild-to-moderate facial acne. The application technique, treatment quantity, and number of layers will follow the approved standard operating procedure and current manufacturer's instructions. All participants will follow a standardized home skin-care regimen using WIQO Nourishing Cream for Normal and Combination Skin and WIQO Balancing Cream. The nourishing cream will be used in the morning and the Balancing Cream in the evening according to the approved study instructions. Home care will continue throughout the treatment and follow-up periods. The regimen will be identical for all participants. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 70
Lasso di tempo: Baseline (Day 0) and Day 70 (14 days after the fifth treatment)
|
The outcome is the within-participant change in the total number of inflammatory facial acne lesions (papules and pustules) between baseline (T0) and T2. Lesions will be counted by a trained dermatologist using a standardized facial lesion-counting procedure. The change will be calculated as the T2 lesion count minus the baseline lesion count. A negative value indicates a reduction in inflammatory lesions. |
Baseline (Day 0) and Day 70 (14 days after the fifth treatment)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 42
Lasso di tempo: Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).
|
Change in the total number of facial inflammatory acne lesions (papules and pustules), counted by a trained dermatologist. The change is calculated as the Day 42 count minus the baseline count. Negative values indicate improvement. |
Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).
|
|
Change From Baseline in Inflammatory Facial Acne Lesion Count at Follow-up
Lasso di tempo: Baseline (Day 0) and T3 (two calendar months after Day 70).
|
Change in the total number of facial inflammatory acne lesions (papules and pustules) between baseline and T3, assessed by a trained dermatologist using standardized lesion counting. Negative values indicate a reduction in inflammatory lesions. |
Baseline (Day 0) and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Comedone Count
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Change in the total number of non-inflammatory facial acne lesions, including open and closed comedones, assessed by a trained dermatologist using standardized lesion counting. The change at each post-baseline visit is calculated as the visit count minus the baseline count. Negative values indicate fewer comedones. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage Reduction From Baseline in Inflammatory Facial Acne Lesion Count
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Percentage reduction in the total number of facial inflammatory acne lesions (papules and pustules), calculated as 100 × (baseline lesion count - post-baseline lesion count) / baseline lesion count. Positive values indicate a reduction in inflammatory lesions. Participants are required to have at least five inflammatory lesions at baseline. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change in Investigator's Global Assessment of Acne Severity
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Acne severity will be assessed by a dermatologist using the static Investigator's Global Assessment (IGA) scale ranging from 0 (clear) to 4 (severe). The distribution of IGA grades and changes in grades from baseline will be reported at each assessment visit. Lower grades indicate less severe acne. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage of Participants Achieving an Investigator's Global Assessment Grade of 0 or 1
Lasso di tempo: Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Percentage of evaluable participants achieving an Investigator's Global Assessment (IGA) grade of 0 (clear) or 1 (almost clear) at each post-baseline assessment. IGA is a five-category ordinal scale ranging from 0 (clear) to 4 (severe). |
Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Percentage of Participants Achieving Investigator's Global Assessment Success
Lasso di tempo: Day 42, Day 70, and T3 (two calendar months after Day 70).
|
IGA success is defined as achieving an Investigator's Global Assessment grade of 0 (clear) or 1 (almost clear), together with an improvement of at least two grades from baseline. Participants with baseline IGA 2 must achieve grade 0, while participants with baseline IGA 3 may achieve grade 0 or 1. |
Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Skin Sebum Level Measured by Sebumetry
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Facial skin surface sebum will be measured using a sebumeter under standardized measurement conditions. Results will be expressed in micrograms per square centimeter (µg/cm²). Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Stratum Corneum Hydration Measured by Corneometry
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Skin hydration will be assessed using corneometry under standardized measurement conditions. Measurements reflect hydration of the stratum corneum and are expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Skin Elasticity (Cutometer R2 Parameter)
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Skin biomechanical properties will be assessed using a Cutometer. The R2 parameter, representing gross skin elasticity, will be recorded as a dimensionless ratio. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Dermal Thickness Measured by Skin Ultrasonography
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Dermal thickness will be measured using skin ultrasonography at standardized anatomical measurement sites. Results will be expressed in millimeters (mm). Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Dermal Echogenicity Measured by Skin Ultrasonography
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Dermal echogenicity will be assessed using skin ultrasonography under standardized acquisition conditions. Results will be expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
|
Change From Baseline in Facial Skin Surface Parameters Assessed by Antera 3D
Lasso di tempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Changes in facial skin surface characteristics, including pore-related parameters, skin texture, and surface roughness, will be assessed using the Antera 3D imaging system. Measurements will be performed at standardized anatomical sites and compared with baseline values. |
Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Anna Deda, PhD, Medical University of Silesia in Katowice, Poland
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- PRXS-SINGLE-2026-01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified individual participant data underlying the reported study results may be made available to qualified researchers upon reasonable request, subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Data sharing will be considered on a case-by-case basis.
Periodo di condivisione IPD
De-identified individual participant data may be made available upon reasonable request following publication of the main study results, subject to participant consent, applicable data protection requirements, and sponsor authorization. The duration of availability will be determined in accordance with the sponsor's data retention and sharing policies.
Criteri di accesso alla condivisione IPD
De-identified individual participant data underlying the published study results may be made available to qualified researchers upon reasonable request. Requests will be reviewed on a case-by-case basis and will be subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Access will be limited to data approved for sharing. Participant-identifiable information and identifiable facial photographs will not be shared without the appropriate consent and legal basis.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .